PD-L1 protein levels could be an important biomarker to predict response to immunotherapy in NSCLC patients.
Among patients with non-small cell lung cancer (NSCLC) treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes. These results from a phase I clinical trial were presented at the American Association for Cancer Research 2014 Annual Meeting, in San Diego, California.
Preliminary data from the trial, which were reported earlier this year, showed that MK-3475 treatment was well tolerated and led to durable, objective responses in previously treated patients with NSCLC, particularly those with tumors found to have high levels of PD-L1 prior to treatment.
The latest results extend these data, showing that at 6 months after starting treatment, 41% of patients whose tumors had high levels of PD-L1 had no disease progression, compared with 17% of those whose tumors had low levels of PD-L1. Similarly, 72% of patients whose tumors had high levels of PD-L1 were alive at this time, compared with 53% of those whose tumors had low levels of PD-L1.
Read the complete report here: http://bit.ly/1mQXGWK
Source: OncologyNurseAdvisor
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More